TY - JOUR
T1 - Prognostic and clinicopathological significance of mir-155 in breast cancer
T2 - A systematic review
AU - Grimaldi, Anna Maria
AU - Nuzzo, Silvia
AU - Condorelli, Gerolama
AU - Salvatore, Marco
AU - Incoronato, Mariarosaria
N1 - Funding Information:
This research was funded by Ministry of Health under contract ?Ricerca Corrente RRC-2020-23669967? to M.I. and S.N., and was partially supported by Associazione Italiana Ricerca sul Cancro (AIRC) IG 2016 N. 18473, POR Campania FESR 2014?2020 ?SATIN? to G.C. and Earlier Grant to G.C. This project has received funding from the European Union?s Horizon 2020 research and innovation programme under the Marie Sk?odowska-Curie grant agreement: cONCReTE 872391; PRISAR2 872860; CAST 857894; PAVE 861190.
Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/8/2
Y1 - 2020/8/2
N2 - There is an unmet need for novel non-invasive prognostic molecular tumour markers for breast cancer (BC). Accumulating evidence shows that miR-155 plays a pivotal role in tumorigenesis. Generally, miR-155 is considered an oncogenic miRNA promoting tumour growth, angiogenesis and aggressiveness of BC. Therefore, many researchers have focused on its use as a prognostic biomarker and therapeutic target. However, its prognostic value for BC patients remains controversial. To address this issue, the present systematic review aims to summarize the available evidence and give a picture of a prognostic significance of miR-155 in BC pathology. All eligible studies were searched on PubMed and EMBASE databases through various search strategies. Starting from 289 potential eligible records, data were examined from 28 studies, comparing tissue and circulating miR-155 expression levels with clinicopathological features and survival rates in BC patients. We discuss the pitfalls and challenges that need to be assessed to understand the power of miR-155 to respond to real clinical needs, highlighting the consistency, robustness or lack of results obtained to sate in translating this molecule to clinical practice. Our paper suggests that the prognostic role of miR-155 in the management of BC needs to be further verified.
AB - There is an unmet need for novel non-invasive prognostic molecular tumour markers for breast cancer (BC). Accumulating evidence shows that miR-155 plays a pivotal role in tumorigenesis. Generally, miR-155 is considered an oncogenic miRNA promoting tumour growth, angiogenesis and aggressiveness of BC. Therefore, many researchers have focused on its use as a prognostic biomarker and therapeutic target. However, its prognostic value for BC patients remains controversial. To address this issue, the present systematic review aims to summarize the available evidence and give a picture of a prognostic significance of miR-155 in BC pathology. All eligible studies were searched on PubMed and EMBASE databases through various search strategies. Starting from 289 potential eligible records, data were examined from 28 studies, comparing tissue and circulating miR-155 expression levels with clinicopathological features and survival rates in BC patients. We discuss the pitfalls and challenges that need to be assessed to understand the power of miR-155 to respond to real clinical needs, highlighting the consistency, robustness or lack of results obtained to sate in translating this molecule to clinical practice. Our paper suggests that the prognostic role of miR-155 in the management of BC needs to be further verified.
KW - Breast cancer
KW - Circulating
KW - Diagnosis
KW - MicroRNA
KW - MiR-155
KW - Prognosis
KW - Tissue
UR - http://www.scopus.com/inward/record.url?scp=85089605120&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089605120&partnerID=8YFLogxK
U2 - 10.3390/ijms21165834
DO - 10.3390/ijms21165834
M3 - Article
C2 - 32823863
AN - SCOPUS:85089605120
VL - 21
SP - 1
EP - 13
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
SN - 1661-6596
IS - 16
M1 - 5834
ER -